Alzheimer Drugs Market - Forecast (2022 - 2027)

The Alzheimer’s Drugs Market size in 2019 is estimated to be $3.5 billion, growing at a CAGR of 6.8% during the forecast period 2022-2027. Alzheimer’s is a progressive neurological disease and the most common form of dementia with symptoms includes memory loss and destroy thinking skills, difficulties with problem-solving or language. The symptoms of Alzheimer’s disease develop slowly for many years and eventually become more severe over a time. The increasing prevalence of the Neurological disorder in the geriatric population and the rising aging population across the globe are the major factors driving the growth of the market. Moreover, growing awareness about the treatment of Alzheimer’s disease across the globe further enhance the overall market demand for Alzheimer’s Drugs during the forecast period 2022-2027.

Report Coverage

The report: “Alzheimer’s Drugs Market - Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Alzheimer’s Drugs Market:

• By Drug Class : Cholinergic, Memantine, Combined drug, and Other drugs.
• By Distribution Channel : Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
• By Geography : North America, Europe, Asia-Pacific, and Rest of the World.

Key Takeaways

• In 2019, North America dominates the Alzheimer’s Drugs Market owing to the increasing prevalence of the neurological disorder among the geriatric population here.
• Increasing the aging population is driving the market growth of the Alzheimer’s Drugs Market.
• Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Alzheimer’s Drugs Market report.
• Difficulty involved in the early diagnosis of indication of Alzheimer’s disease is challenging the growth of the market.

Alzheimer’s Drugs Market Segment Analysis - Drug Class

Based on the Drug Class, Alzheimer’s Drugs Market is segmented into Cholinergic, Memantine, Combined drug, and other drugs. The Memantine segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 5.4% during the forecast period 2022-2027. This is mainly owing to the growing purchasing power and disposable income of the people that are contributing to increased sales of this drug class. Moreover, it is used to treat symptoms like confusion, improves memory and brain function, which further drives the market.

Alzheimer’s Drugs Market Segment Analysis - Distribution Channel

Based on the Distribution channel, Alzheimer’s Drugs Market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In 2019, Hospital Pharmacies held the largest share in the Alzheimer’s Drugs Market. This is mainly owing to the availability of cost-effective medicine for the treatment of Alzheimer’s which driving the market. Most of the Alzheimer’s drugs are prescription only, this is contributing to the high sales of these drugs through hospital pharmacies. However, online pharmacies are poised to grow the fastest over the forecast period 2022-2027. This is owing to the increased adoption of online pharmacies and benefits offered by online channels such as ease of availability and convenience.

Alzheimer’s Drugs Market Segment Analysis - Geography

In 2019, North America dominated the Alzheimer’s Drugs market share accounting for XX% of the market. This is mainly owing to the increasing prevalence of the neurological disorder in the geriatric population in this region. According to U.S. Food and Drug Administration FDA, in 2017, more than 5.8 Million American have Alzheimer’s which increases the demand of the Alzheimer’s Drugs Market.

However, the Asia-Pacific region is projected to be the fastest-growing during the forecast period 2022-2027. This is owing to increasing awareness among people about the treatment of Alzheimer’s disease.

Alzheimer’s Drugs Market Drivers

Increasing Prevalence of the neurological disorder

According to World Health Organization (WHO), around 50million people have dementia, which is a common form of Alzheimer’s disease and there are 10 million new cases every year. The high prevalence of such diseases drive the growth of these drugs as well. Thus, the increasing prevalence of the neurological disorder in the geriatric population across the globe is driving the growth of the Alzheimer’s Drugs market.

Growing Awareness about Alzheimer’s Treatment

Growing awareness among the people about the treatment of Alzheimer’s disease in worldwide is driving the growth of the market. Moreover, people are also gaining awareness on the various innovative treatment options and this is further contributing to the growth of the Alzheimer’s Drugs Market.

Alzheimer’s Drugs Market Challenges

The difficulty involved in the early diagnosis of indication of Alzheimer’s disease is challenging the growth of the market. Moreover high cost of R&D activities for drug development is further restraining its market growth during the forecast period 2022-2027.

Alzheimer’s Drugs Industry Outlook

Product launches, Merger & Acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Alzheimer’s Drugs Market. Alzheimer’s Drug top 10 companies are Johnson & Johnson Services, Bayer AG, Ono Pharmaceutical Co. Ltd, Eli Lilly and Company, GE Healthcare, Roche AG, Genentech Inc., AB Science, AC Immune and Biogen.

Developments:

• On August 2020, Biogen announced FDA acceptance of the Biologics License Application (BLA) for Aducanumab, an investigational treatment for Alzheimer’s disease.

This product will be delivered within 2 business days.